AIKIDO PHARMA INC (AIKI)       3.56  +0.01 (+0.28%)

3.56  +0.01 (+0.28%)

US0088753043 - Common Stock


Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to AIKI. AIKI was compared to 640 industry peers in the Biotechnology industry. The financial health of AIKI is medium. Also its profitability is quite bad. AIKI has a expensive valuation and it also scores bad on growth

Note: AIKI has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

AIKI has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of AIKI.

VS Industry

Valuation

Valuation Rating

3

When comparing the current price to the book value of AIKI, it is valued rather cheaply. It is trading at 0.24 times its book value.
Compared to an average industry price book ratio of 1.89, AIKI is valued rather cheaply. On top of this, AIKI is cheaper than 98% of the companies listed in the same industry.

AIKI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AIKI. No positive earnings are expected for the next year.
VS Industry

Price/Book (0.24) VS Industry: 98% outperformed.

448.49
0.07

Growth

Growth Rating

2

Based on estimates for the next 5 years, AIKI will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.65% on average per year.

The earnings per share for AIKI have decreased strongly by -879.05% in the last year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -879.05% -245.59% -5.02% 23.38% 11.65%
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating

6

A Current Ratio of 29.54 indicates that AIKI has no problem at all paying its short term obligations.
AIKI is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 6.21. AIKI has a better rating than 96% of its industry peers.
AIKI has a Quick Ratio of 29.54. This indicates that AIKI is financially healthy and has no problem in meeting its short term obligations.
AIKI is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 6.11. AIKI has a better rating than 96% of its industry peers.

When comparing the Altman-Z score to an average industry score of 0.01, AIKI is in better financial health than the average industry peer.
The Debt to Equity ratio of AIKI is in line with the industry averages.
Based on the Altman-Z score of 1.78, we must say that AIKI is in the distress zone and has some risk of bankruptcy.
The Piotroski-F score of AIKI is 3.00. This is a low score and indicates issues in the health and profitability of AIKI.
VS Industry

Debt/Equity (0) VS Industry: 42% outperformed.

15.37
0.00

Quick Ratio (29.54) VS Industry: 96% outperformed.

0.04
84.53

Current Ratio (29.54) VS Industry: 96% outperformed.

0.08
85.09

Altman-Z (1.78) VS Industry: 61% outperformed.

-94.26
670.27

Dividend

Dividend Rating

0

AIKI does not give a dividend.

AIKIDO PHARMA INC3.56

NASDAQ:AIKI (12/21/2022, 7:17:10 PM)+0.01 (+0.28%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-10 2022-11-10/amc Earnings (Next) 03-27 2023-03-27
Inst Owners N/A Inst Owner Change N/A
Ins Owners 4.37% Ins Owner Change 199.04%
Market Cap 19.53M Analysts 82.86
Price Target 16.32 (358.43%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP N/A
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) N/A Avg EPS beat(2) -59.55%
Min EPS beat(2) -70.13% Max EPS beat(2) -48.97%
EPS beat(4) N/A Avg EPS beat(4) -77.81%
Min EPS beat(4) -96.08% Max EPS beat(4) -48.97%
Revenue beat(2) N/A Avg Revenue beat(2) N/A
Min Revenue beat(2) N/A Max Revenue beat(2) N/A
Revenue beat(4) N/A Avg Revenue beat(4) N/A
Min Revenue beat(4) N/A Max Revenue beat(4) N/A
PT rev (1m) -55.56% PT rev (3m) N/A
EPS NQ rev (1m) 0% EPS NQ rev (3m) N/A
EPS NY rev (1m) -17.5% EPS NY rev (3m) N/A
Revenue NQ rev (1m) N/A Revenue NQ rev (3m) N/A
Revenue NY rev (1m) N/A Revenue NY rev (3m) N/A

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.24
P/tB 0.22
EV/EBITDA N/A
EPS(TTM) -3.37 EY N/A
EPS(NY) -1.53 Fwd EY N/A
FCF(TTM) -2.07 FCFY N/A
OCF(TTM) -1.97 OCFY N/A
SpS N/A BVpS 14.92
TBVpS 15.92 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM N/A
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y N/A GM growth 5Y N/A
F-Score 3 Asset Turnover N/A

Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Profit Quality N/A
Current Ratio 29.54
Quick Ratio 29.54
Altman-Z 1.78
F-Score 3 WACC N/A
ROIC/WACC N/A Cap/Depr(3y) N/A
Cap/Depr(5y) N/A Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y -879.05% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -12993.62%
EPS Next Y -245.59% EPS Next 2Y -5.02%
EPS Next 3Y 23.38% EPS Next 5Y 11.65%
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
EBIT growth 1Y -67.16% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year N/A
EBIT Next 3Y N/A EBIT Next 5Y N/A
FCF growth 1Y -92.65% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -146.75%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA